Related Experiment Video
Updated: Aug 11, 2026

Isokinetic Robotic Device to Improve Test-Retest and Inter-Rater Reliability for Stretch Reflex Measurements in Stroke Patients with Spasticity
Published on: June 12, 2019
[Botulinum toxin--interventional neuropediatrics in spastic movement disorders in childhood]
Steffen Berweck1, Florian Heinen
1Klinik für Kinderheilkunde und Jugendmedizin, Klinikum Duisburg, Wedau Klinikin, Duisburg. berweck@childbrain.de
Insights
Botulinum toxin A (BTX) effectively treats childhood spastic movement disorders, improving motor skills and brace tolerance. This review clarifies proven versus suspected clinical uses for BTX in pediatric patients.
Area of Science:
- Neurology
- Pediatrics
- Pharmacology
Context:
- Botulinum toxin A (BTX) is a key therapeutic agent for pediatric spastic movement disorders.
- Extensive clinical experience and trials support the safety and local efficacy of BTX in children.
- Current applications aim to improve daily care, orthotic device tolerance, and motor function.
Purpose:
- To differentiate established clinical indications for BTX in pediatric spasticity from those requiring further investigation.
- To provide a clear overview of the evidence base for BTX use in childhood neurological conditions.
Summary:
- BTX demonstrates well-documented safety and efficacy in treating spastic movement disorders in children.
- Proven indications include enhancing care facilitation, improving orthotic tolerance, and enhancing motor abilities.
- The article distinguishes between BTX applications with robust evidence and those with suspected or unclear effectiveness.
Impact:
- Provides clinicians with evidence-based guidance for utilizing BTX in pediatric spasticity management.
- Aids in optimizing treatment strategies for children with movement disorders.
- Highlights areas for future research to clarify the efficacy of BTX in less-established indications.
Abstract:
Botulinumtoxin A (BTX) is widely used for the treatment of spastic movement disorders in childhood. Safety and local efficacy of BTX are well documented by the experience of many users and verified by several clinical trials. Indications for the use of BTX in children include facilitation of care, better tolerance of ortheses as well as the quantitative and qualitative improvement of motor abilities. This article differentiates clinical indications for which the use of BTX has been proven from those in which effectiveness is only suspected or is yet unclear.
Related Concept Videos
Classification of Skeletal Muscle Relaxants
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
Skeletal Muscle Relaxants: Therapeutic Uses
Tetanus
Botulism
Alterations in Muscle Tone ll

